Date: 2016-05-02
Type of information: Opening of new premises
Compound: new facility at Martillac (France)
Company: Merck KGaA (Germany)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On May 2, 2016, Merck KGaA announced the expansion of its single use current good manufacturing process (cGMP) facility with the addition of the Mobius® 2000L single-use bioreactor. With the new upstream suite at its Biodevelopment Center in Martillac (France), Merck KGaA can now offer clients full process line cGMP manufacturing, comprised of Merck’s own instrumentation and products. With this increase in scale and scope, Merck KGaA can advance clients’ recombinant products from cell line development through to late-stage clinical production. Merck KGaA’s Provantage® End-to-End solution is a comprehensive suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialization. The offering aims to minimize the risks for customers progressing from early clinical stages to commercial production helping to accelerate time to market and improve productivity and profitability.
Financial terms:
Latest news:
